Moneycontrol PRO
HomeNewsBusinessCompaniesMorgan Stanley downgrades Cipla to 'underweight'

Morgan Stanley downgrades Cipla to 'underweight'

Morgan Stanley downgrades Cipla Ltd to "underweight" from "equal-weight", citing slower growth prospects and valuations.

August 13, 2013 / 14:12 IST

Morgan Stanley downgrades Cipla Ltd to "underweight" from "equal-weight" and reduces its target price on the stock to 386 rupees from 414 rupees citing slower growth prospects and valuations.

The bank adds that the drugmaker's move to build a marketing and sales front-end operation in the United States and Europe will yield results only in the longer term.

Also read:Cipla Q1 net profit jump 10%, revenue rise by 19%

Morgan Stanley's downgrade comes a day after Macquarie upgraded Cipla to "outperform" from "neutral", saying the drugmaker's April-June earnings were "significantly above" their estimates.

Cipla on Saturday posted an 18.5 percent jump in April-June net profit to 4.75 billion rupees.

Cipla shares are up 1.8 percent at 12.14 p.m.

first published: Aug 13, 2013 01:40 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347